References of "Reginster, Jean-Yves"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailEffects of Dairy Products Consumption on Health: Benefits and Beliefs-A Commentary from the Belgian Bone Club and the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases.
Rozenberg, Serge; Body, Jean-Jacques; Bruyère, Olivier ULg et al

in Calcified Tissue International (2016), 98(1), 1-17

Dairy products provide a package of essential nutrients that is difficult to obtain in low-dairy or dairy-free diets, and for many people it is not possible to achieve recommended daily calcium intakes ... [more ▼]

Dairy products provide a package of essential nutrients that is difficult to obtain in low-dairy or dairy-free diets, and for many people it is not possible to achieve recommended daily calcium intakes with a dairy-free diet. Despite the established benefits for bone health, some people avoid dairy in their diet due to beliefs that dairy may be detrimental to health, especially in those with weight management issues, lactose intolerance, osteoarthritis, rheumatoid arthritis, or trying to avoid cardiovascular disease. This review provides information for health professionals to enable them to help their patients make informed decisions about consuming dairy products as part of a balanced diet. There may be a weak association between dairy consumption and a possible small weight reduction, with decreases in fat mass and waist circumference and increases in lean body mass. Lactose intolerant individuals may not need to completely eliminate dairy products from their diet, as both yogurt and hard cheese are well tolerated. Among people with arthritis, there is no evidence for a benefit to avoid dairy consumption. Dairy products do not increase the risk of cardiovascular disease, particularly if low fat. Intake of up to three servings of dairy products per day appears to be safe and may confer a favourable benefit with regard to bone health. [less ▲]

Detailed reference viewed: 36 (20 ULg)
Full Text
Peer Reviewed
See detailEfficacy and safety of hyaluronic acid in the management of osteoarthritis : Evidence from real-life setting trials and surveys.
Maheu, E.; Rannou, F.; Reginster, Jean-Yves ULg

in Seminars in Arthritis & Rheumatism (2016), 45(4 Suppl), 28-33

The European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) treatment algorithm recommends intra-articular (IA) hyaluronic acid (HA) for management of knee ... [more ▼]

The European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) treatment algorithm recommends intra-articular (IA) hyaluronic acid (HA) for management of knee osteoarthritis (OA) as second-line treatment in patients who remain symptomatic despite use of non-steroidal anti-inflammatory drugs (NSAIDs). This recommendation is based upon accumulating evidence that IA HA provides a significant benefit in knee OA. There is good evidence that IA HA injections reduce pain and increase function in knee OA, and the benefits are long-lasting as compared with IA corticosteroids. Evidence from real-life studies of repeat courses of IA HA demonstrates an improvement in pain or function lasting up to 40 months (12 months after the last injection cycle), a reduction in use of concomitant analgesia by up to 50%, and suggests that there may be a delay in the need for total knee replacement (TKR) of around 2 years. The clinical benefit of IA HA on knee OA may be 2-fold: (i) mechanical viscosupplementation of the joint (allowing lubrication and shock absorption) and (ii) the re-establishment of joint homeostasis through induction of endogenous HA production, which continues long after the exogenous injection has left the joint.The magnitude of the clinical effect may be different for different HA products, but this has not been proven so far and requires further investigation. IA HA injections are generally considered to be safe,although a slightly higher number of cases of local reactions and post-injection non-septic arthritis has been reported with high molecular weight cross-linked HAs. The use of IA HA in knee OA patients with mild–moderate disease, and for more severe patients wishing to delay TKR surgery,is recommended by the ESCEO taskforce. Further investigation into the OA patient types most likely to benefit from IA HA is warranted. Viscosupplementation with IA HA is a safe and effective component of the multi-modal management of knee OA. [less ▲]

Detailed reference viewed: 19 (6 ULg)
Full Text
Peer Reviewed
See detailThe role of diet and exercise and of glucosamine sulfate in the prevention of knee osteoarthritis: Further results from the PRevention of knee Osteoarthritis in Overweight Females (PROOF) study.
Runhaar, J.; DEROISY, Rita ULg; van Middelkoop, M. et al

in Seminars in Arthritis & Rheumatism (2016), 45(4 Suppl), 42-48

Background and objectives: The PRevention of knee Osteoarthritis in Overweight Females(PROOF) study (ISRCTN42823086) described a trend for a decrease in the incidence of kneeo steoarthritis (OA) by a ... [more ▼]

Background and objectives: The PRevention of knee Osteoarthritis in Overweight Females(PROOF) study (ISRCTN42823086) described a trend for a decrease in the incidence of kneeo steoarthritis (OA) by a tailored diet and exercise program (DEP)or by oral glucosamine sulfate in women at risk for the disease, using a composite clinical and/or radiological outcome. The aim of this updated post-hoc analysis was to re-assess the results according to more precise techniques and take advantage of the 2 x 2 factorial design. Methods: A total of 407 overweight( BMI > or egal 27kg/m2) women of 50–60 years of age with no diagnosis of knee OA were randomized to: (1) noDEP + placebo(Control, N = 102), (2) DEP + placebo (DEP, N = 101), (3) glucosamine sulfate + no DEP (GS, N = 102), and (4) DEP + glucosamine sulfate (DEP + GS, N = 102) and followed for 2.5 years, with standardized postero-anterior, semiflexed (MTP) view knee radiographs at baseline and end of the study. DEP consisted of a tailored low fat and/or low caloric diet and easy to implement physical activities. Glucosamine was given as oral crystalline glucosamine sulfate 1500 mg once daily ,double-blinded vs. placebo. Incident knee OA was defined as radiographic progression of >1mm minimum joint space narrowing (mJSN)in the medial tibiofemoral compartment, as previously assessed by the visual (manual) technique and by a new semi-automated method. Logistic regression analysis was used t ocalculate the odds ratio for the effect of the interventions. Results: After 2.5 years, 11.8% of control subjects developed knee OA. This incidence was decreased with glucosamine sulfate, either alone or in combination with the DEP, but not by the DEP alone. Since there was no statistical interaction between treatments, the 2x2 factorial design allowed analysis of patients receiving glucosamine sulfate (N = 204) vs. those not receiving it (N= 203), similarly for those on the DEP (N = 203) or not (N = 204). Glucosamine sulfate significantly decreased the risk of developing knee OA: odds ratio (OR) = 0.41(95% CI: 0.20–0.85, P = 0.02) by the manual JSN assessment method and OR = 0.42 (95% CI:0.20–0.92, P =0.03) by the semi-automated technique. Conversely, there was no decrease in risk with the DEP. Conclusions: Glucosamine sulfate decreased the risk of developing radiographic knee OA over 2.5 years in overweight, middle-aged women at risk, as determined by medial mJSN progression. Conversely a tailored diet and exercise program exerted no preventive effect, possibly because of the lower than expected effect on weigh tloss. [less ▲]

Detailed reference viewed: 42 (7 ULg)
Full Text
Peer Reviewed
See detailOptimizing the management of osteoarthritis-Transitioning evidence-based guidelines into practical guidance for real-world clinical practice
Reginster, Jean-Yves ULg; Cooper, C.

in Seminars in Arthritis & Rheumatism (2016), 45(4 Suppl), 1-2

Detailed reference viewed: 22 (10 ULg)
Full Text
Peer Reviewed
See detailEfficacy and safety of glucosamine sulfate in the management of osteoarthritis: Evidence from real-life setting trials and surveys.
Bruyère, Olivier ULg; Altman, R.D.; Reginster, Jean-Yves ULg

in Seminars in Arthritis & Rheumatism (2016), 45(4 Suppl), 12-17

The European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) treatment algorithm recommends chronic symptomatic slow-acting drugs for osteoarthritis (SYSADOAs ... [more ▼]

The European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) treatment algorithm recommends chronic symptomatic slow-acting drugs for osteoarthritis (SYSADOAs) including glucosamine sulfate (GS) and chondroitin sulfate (CS) as first-line therapy for knee osteoarthritis (OA). Numerous studies are published on the use of SYSADOAs in OA; however, the efficacy of this class is still called into question largely due to the regulatory status, labeling and availability of these medications which differ substantially across the world. Examination of the evidence for the prescription patented crystalline GS (pCGS) formulation at a dose of 1500 mg once-daily demonstrates superiority overother GS and glucosamine hydrochloride (GH) formulations and dosage regimens. Thus, the ESCEO task force advocates differentiation of prescription pCGS over other glucosamine preparations. Long-term clinical trials andreal-life studies show that pCGS may delay joint structural changes, suggesting potential benefit beyond symptom control when used early in the management of knee OA. Real-life pharmacoeconomic studies demonstrate a long-term reduction in the need for additional pain analgesia and non-steroidal anti-inflammatory drugs (NSAIDs) with pCGS, with a significant reduction of over 50% in costs associated with medications, healthcare consultations and examinations over 12 months. Furthermore, treatment with pCGS for at least 12 months leads to a reduction in the need for total joint replacement for at least 5 years following treatment cessation. Thus, pCGS(1500 mg od) is a logical choice to maximize clinical benefit in OA patients, with demonstrated medium-term control of pain and lasting impact on disease progression. [less ▲]

Detailed reference viewed: 22 (7 ULg)
Full Text
Peer Reviewed
See detailA consensus statement on the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) algorithm for the management of knee osteoarthritis - From evidence-based medicine to the real-life setting.
Bruyère, Olivier ULg; Cooper, C.; Pelletier, J.P. et al

in Seminars in Arthritis & Rheumatism (2016), 45(4 Suppl), 3-11

The European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis(ESCEO) published a treatment algorithm for the management of knee osteoarthritis (OA) in 2014,which provides ... [more ▼]

The European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis(ESCEO) published a treatment algorithm for the management of knee osteoarthritis (OA) in 2014,which provides practical guidance for the prioritization of interventions. Further analysis of real-world data for OA provides additional evidence in support of pharmacological interventions,in terms of management of OA pain and function, avoidance of adverse events, disease-modifying effects and long-term outcomes, e.g., delay of total joint replacement surgery, and pharmacoeconomic factors such as reduction in healthcare resource utilization. This article provides an updated assessment of the literature for selected interventions in OA, focusing on real-life data, with the aim of providing easy-to-follow advice on how to establish a treatment flow in patients with knee OA in primary care clinical practice, in support of the clinicians’ individualized assessment of the patient. In step 1, background maintenance therapy with symptomatic slow-acting drugs for osteoarthritis (SYSADOAs) is recommended, for which high-quality evidence is provided only for the prescription formulations of patented crystalline glucosamine sulfate and chondroitin sulfate. Paracetamol may be added for rescue analgesia only,due to limited efficacy and increasing safety signals. Topical non-steroidal anti-inflammatory drugs (NSAIDs) may provide additional symptomatic treatment with the same degree of efficacy as oral NSAIDs without the systemic safety concerns. Oral NSAIDs maintain a central role in step2 Advanced management of persistent symptoms. However, oral NSAIDs are highly heterogeneous in terms of gastrointestinal and cardiovascular safety profile, and patient stratification with careful treatment selection is advocated to maximize the risk: benefit ratio. Intra-articular hyaluronic acid as a next step provides sustained clinical benefit with effects lasting up to 6 months after a short-course of weekly injections. As a last step before surgery, thes low titration of sustained-release tramadol, aweak opioid, affords sustained analgesia with improved tolerability. [less ▲]

Detailed reference viewed: 27 (12 ULg)
Full Text
Peer Reviewed
See detailLe couplage « Micro-crédit, Micro-assurance santé et Offre des soins » peut améliorer l’accessibilité aux soins de santé de qualité en milieu urbain africain : Résultats d’une expérience menée dans la zone de santé de Bandalungwa à Kinshasa, Congo.
Manzambi Kuwekita, Joseph ULg; Gosset, Christiane ULg; Guillaume, Michèle ULg et al

in Médecine et Santé Tropicales (2015), 25

Summary This study, based on a survey carried out in 2008, examines how coupling «microcredit, micro-insurance and health care» can improve access to quality care in the health zone of Bandalungwa, in ... [more ▼]

Summary This study, based on a survey carried out in 2008, examines how coupling «microcredit, micro-insurance and health care» can improve access to quality care in the health zone of Bandalungwa, in Kinshasa. The bivariate analysis shows a significant association between the increase in purchasing power and realization of benefit (p = 0, 001), achievement of benefit and savings (p = 0, 000) savings and insurance health and improved access to health care: according to the main results, 68.8 %t of borrowers reported an increase in their purchasing power which 81.8% making benefit. Those with savings were 24.7 times more likely to contribute to a health insurance scheme than those without; 71.9% of those who have regularly contributed to health insurance have improved their access to care. Coupling microcredit, health microinsurance and health care can improve access to quality health care at lower cost. This suggests the integration of health insurance in the primary health care system. [less ▲]

Detailed reference viewed: 190 (44 ULg)
Full Text
Peer Reviewed
See detailPublic health impact and cost-effectiveness of dairy products supplemented with vitamin D in prevention of osteoporotic fractures
Ethgen, Olivier ULg; Hiligsmann, Mickaël; Burlet, Nansa et al

in Archives of Public Health (2015)

Background: Dietary sources of calcium and vitamin D are recommended as a first-line strategy in prevention of osteoporosis-related fractures but their public health and economic impact has never been ... [more ▼]

Background: Dietary sources of calcium and vitamin D are recommended as a first-line strategy in prevention of osteoporosis-related fractures but their public health and economic impact has never been studied. Methods: We designed a population-based model to forecast the potential health outcomes and medical effectiveness of the daily administration of dairy supplements containing 800 IU of vitamin D and 1 g of calcium in cohorts of subjects, from both genders, aged 50, 60, 70 and 80 years. Annual costs of dairy products were tested at €150, €250 and €350. Results: In total, the daily intake of vitamin-D rich dairy products reduces by 30,376 and 16,105 events the number of osteoporotic fractures in women and men respectively and permits to gain 6605 and 6144 life-years, in women and men respectively. This intervention is cost-effective from 70 years on in the general population and from 60 years on in patients at increased risk of osteoporotic fractures. Conclusion: The recommendation to use dairy products as the preferred source of calcium and vitamin D in aging males and females is supported by public health and health economic analyses. [less ▲]

Detailed reference viewed: 10 (7 ULg)
Full Text
Peer Reviewed
See detailQualité de vie du patient sarcopénique : apport de l’étude liégeoise SarcoPhAge
Beaudart, Charlotte ULg; Reginster, Jean-Yves ULg; PETERMANS, Jean ULg et al

in Gériatrie et Psychologie Neuropsychiatrie du Vieillissement (2015), 13(4), 391-5

The consequences of sarcopenia on quality are difficult to evaluate and consequently are quite poorly studied. The few studies assessing the quality of life in sarcopenic subjects currently use generic ... [more ▼]

The consequences of sarcopenia on quality are difficult to evaluate and consequently are quite poorly studied. The few studies assessing the quality of life in sarcopenic subjects currently use generic quality of life questionnaires such as SF36 and EQ5D. The SarcoPhAge study, conducted on a cohort developed in Liège including 534 subjects of 65 years or older, suggested that sarcopenic subjects present a significant worse quality of life in the domains of physical function compared to nonsarcopenic subjects. Generic tools do not cover exhaustively all the areas of potential dysfunction concerned in this geriatric syndrome. Yet, there is no specific and validated quality of life questionnaire for sarcopenia. It would be useful to have at our disposal a sarcopenia specific quality of life questionnaire to assess not only the prospective quality of life of sarcopenic subjects but also to assess the efficacy and the rele [less ▲]

Detailed reference viewed: 40 (10 ULg)
Full Text
Peer Reviewed
See detailThe effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study.
PAPAPOULOS, S.; LIPPUNER, K.; ROUX, C. et al

in Osteoporosis International (2015), 26(12), 2773-2783

Summary: The FREEDOM study and its Extension provide long-term information about the effects of denosumab for the treatment of postmenopausal osteoporosis. Treatment for up to 8 years was associated with ... [more ▼]

Summary: The FREEDOM study and its Extension provide long-term information about the effects of denosumab for the treatment of postmenopausal osteoporosis. Treatment for up to 8 years was associated with persistent reduction of bone turnover, continued increases in bone mineral density, low fracture incidence, and a favorable benefit/risk profile. Introduction: This study aims to report the results through year 5 of the FREEDOM Extension study, representing up to 8 years of continued denosumab treatment in postmenopausal women with osteoporosis. Methods : Women who completed the 3-year FREEDOM study were eligible to enter the 7-year open-label FREEDOM Extension in which all participants are scheduled to receive denosumab, since placebo assignment was discontinued for ethical reasons. A total of 4550 women enrolled in the Extension (2343 long-term; 2207 cross-over). In this analysis, women in the long-term and cross-over groups received denosumab for up to 8 and 5 years, respectively. Results Throughout the Extension, sustained reduction of bone turnover markers (BTMs) was observed in both groups. In the long-term group, mean bone mineral density (BMD) continued to increase significantly at each time point measured, for cumulative 8-year gains of 18.4 and 8.3 % at the lumbar spine and total hip, respectively. In the cross-over group, mean BMD increased significantly from the Extension baseline for 5-year cumulative gains of 13.1 and 6.2 % at the lumbar spine and total hip, respectively. The yearly incidence of new vertebral and nonvertebral fractures remained low in both groups. The incidence of adverse and serious adverse events did not increase over time. Through Extension year 5, eight events of osteonecrosis of the jaw and two events of atypical femoral fracture were confirmed. [less ▲]

Detailed reference viewed: 20 (3 ULg)
Full Text
Peer Reviewed
See detailAssessment of muscle mass, muscle strength and physical performance in clinical practice: An international survey
Bruyère, Olivier ULg; Beaudart, Charlotte ULg; Reginster, Jean-Yves ULg et al

in European Geriatric Medicine (2015)

Introduction: Several tools are available for the assessment of muscle mass, muscle strength and physical performance in clinical research. However, few data are available on the usage of these tools in ... [more ▼]

Introduction: Several tools are available for the assessment of muscle mass, muscle strength and physical performance in clinical research. However, few data are available on the usage of these tools in clinical practice. Methods: This study aimed to assess their usage by means of a large online international survey. Since sarcopenia is a specific condition where the assessment of muscle mass, muscle strength and physical performance is important, the survey also assessed the tools used for the diagnosis of this geriatric syndrome. Results: The survey was completed by 255 clinicians from 55 countries across 5 continents. Among these clinicians with geriatrics, rheumatology and endocrinology as major fields of interest, 53.3% assess muscle mass in daily practice, 54.5% muscle strength and 71.4% physical performance. However, the tools used are very different and no single tool is used by all clinicians. The tools and the cut-off values used by clinicians to diagnose sarcopenia are also heterogeneous. Conclusion: Because some tools used for the assessment of muscle mass, muscle strength or physical performance in daily practice are less validated than others, a greater awareness from the clinicians of the importance of using appropriate tools is needed [less ▲]

Detailed reference viewed: 49 (4 ULg)
Full Text
Peer Reviewed
See detailLe tradipraticien est un acteur incontournable dans l’offre des soins de santé en territoire péri-urbain : équilibre entre légitimité et illégalité ?
Manzambi Kuwekita, Joseph ULg; Mbadu Kivuidi, Véronique; Bruyère, Olivier ULg et al

in Halleux, Jean-Marie; Bogaert, Jan (Eds.) Territoires Périurbains (2015)

Summary This study examines people’s and public actors’s perception of traditional healers in Kisenso, and their potential integration into the health system. The findings of this study are based on focus ... [more ▼]

Summary This study examines people’s and public actors’s perception of traditional healers in Kisenso, and their potential integration into the health system. The findings of this study are based on focus groups conducted in 2013. According to the key results of this study, 100% of participants acknowledge the existence of traditional practitioners and all have used them. 80% found the care provided by these healers to be effective. However, the study participants found them to be lacking in hygiene in their handling of products. The use of traditional healers is justified in particular by the effectiveness of care, the type of illness suffered, the possibility of credit payment and their proximity. Public actors recognize both the existence of traditional healers and their effectiveness. They deplore their clandestine operation. Traditional healers claiming to be GPs (60%) and specialists (40%) say they work illegally because of the cost of administrative acts and their mistrust of intellectuals and biomedical practitioners. They complain about the insolvency of their patients who do not honor their commitments. For an effective integration of traditional healers in the health system, it would be useful to remove administrative barriers imposed on them for a balance between ancestral legitimacy and illegality in which they work, give them access to training, accept them as full participants in the health system, and explore the possibilities of contracting. [less ▲]

Detailed reference viewed: 81 (27 ULg)
Full Text
Peer Reviewed
See detailPourcentage de femmes atteignant des T-scores de DMO non ostéoporotiques au rachis lombaire (RL) et à la hanche totale (HT) après 8 ans de traitement par denosumab (DMAb)
Ferrari, S.; Libanati, C.; Lin, J. et al

in Revue du Rhumatisme (2015, November), 82(S1), 35-36

Detailed reference viewed: 25 (2 ULg)
Full Text
Peer Reviewed
See detailTraitement par denosumab chez des hommes à masse osseuse basse: résultats à 24 mois de l'étude ADAMO
Chapurlat, R.; Langdahl, B.; Teglbjaerg, C. et al

in Revue du Rhumatisme (2015, November), 82(S1), 123-124

Detailed reference viewed: 18 (2 ULg)
Full Text
Peer Reviewed
See detailEnergy and nutrient contents of food served and consumed by nursing home residents
Buckinx, Fanny ULg; Paquot, Nicolas ULg; Allepaerts, Sophie ULg et al

in European Geriatric Medicine (2015, September), 6S1

Detailed reference viewed: 41 (7 ULg)
Full Text
Peer Reviewed
See detailImpact of the frailty status on muscle mass and muscle strength of nursing home residents
Buckinx, Fanny ULg; Croisier, Jean-Louis ULg; Reginster, Jean-Yves ULg et al

in European Geriatric Medicine (2015, September), 6S1

Detailed reference viewed: 17 (1 ULg)
Full Text
Peer Reviewed
See detailCorrelation between muscle mass and muscle strength among nursing home residents
Buckinx, Fanny ULg; Croisier, Jean-Louis ULg; Reginster, Jean-Yves ULg et al

in European Geriatric Medicine (2015, September), 6S1

Detailed reference viewed: 17 (4 ULg)
Full Text
Peer Reviewed
See detailDevelopment and validation of a self-administrated quality of life questionnaire specific to sarcopenia: the SarQol
Beaudart, Charlotte ULg; Reginster, Jean-Yves ULg; Rizzoli, R. et al

in European Geriatric Medicine (2015, September), 6S1

Detailed reference viewed: 27 (2 ULg)